E7777
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-cell Lymphoma
Conditions
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Trial Timeline
Mar 28, 2016 → Apr 26, 2019
NCT ID
NCT02676778About E7777
E7777 is a phase 2 stage product being developed by Eisai for Peripheral T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02676778. Target conditions include Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02676778 | Phase 2 | Completed |
| NCT01355783 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Peripheral T-cell Lymphoma